Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Advanced CML or Ph+ ALL Pre- and Post-Transplant
NCT00750659Phase 2Completed
- Sponsor
- Sheba Medical Center
- Start
- Jul 2009
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), sponsored by Sheba Medical Center. Primary endpoint: Safety at 12 months. Started Jul 2009; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00750659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00750659.